id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-2997-0001,FDA,FDA-2022-D-2997,"Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards; Availability",Proposed Rule,GDL Guidance,2024-03-01T05:00:00Z,2024,3,2024-03-01T05:00:00Z,,2024-03-01T16:26:43Z,2024-04377,0,0,0900006486448247
FDA-2022-D-2997-0002,FDA,FDA-2022-D-2997,"Key Information and Facilitating Understanding in Informed Consent
Guidance for Sponsors, Investigators, and Institutional Review Boards - Draft Guidance",Other,Guidance,2024-03-01T05:00:00Z,2024,3,2024-03-01T05:00:00Z,2024-05-01T03:59:59Z,2024-11-12T22:23:52Z,,1,0,0900006486449663